Results for
"[search-keyword]"
Sponsor content
310 result(s) found, displaying 121 to 130
-
Prescription medicine decision summaryTGA decision: Koselugo (selumetinib) is approved to treat paediatric patients aged 2 years and above, with neurofibromatosis type 1 (NF1)
-
-
Designation or determinationProvisional determination
-
Australian Public Assessment Report (AusPAR)Australian Public Assessment Report for ChAdOx1-S - COVID-19 Vaccine AstraZeneca
-
-
Designation or determinationPriority Review
-
Prescription medicine registrationActive ingredients: trastuzumab deruxtecan.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for BRICANYL TURBUHALER terbutaline sulfate 400 microgram powder for inhalation dry powder inhaler.
-
Prescription medicine registrationActive ingredients: dapagliflozin propanediol monohydrate.
-
Prescription medicine registrationActive ingredients: dapagliflozin propanediol monohydrate.